Hwa-Jung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hwa-Jung Kim has a total of 501 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Kyu Park
Department of Microbiology and Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon, Korea
45 shared publications - Chang-Hwa Song
Department of Medical Science, College of Medicine Chungnam National University Daejeon Republic of Korea
36 shared publications - Eun-Kyeong Jo
Department of Microbiology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
34 shared publications - Sung Jae Shin
Department of Microbiology, Institute for Immunology and Immunological Disease, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea
29 shared publications Han-Gyu Choi
Department of Microbiology and Medical Science, College of Medicine, Chungnam National University, 266 Munhwa-ro, Jung-gu, Daejeon 35015, South Korea; Translational Immunology Institute, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, South Korea
21 shared publicationsYong Woo Back
R&D Center, Myco-Rapha Inc., Daejeon 35015, South Korea
19 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (11)
Integrated Computational Pipeline Combining Metabolomics and Network Pharmacology for Bioactive Scaffold Discovery: Application to Antarctic Moss Chorisodontium aciphyllum
Discovering lead compounds from complex natural matrices traditionally requires resource‐intensive isolation steps. Integrating computational biology with untargeted metabolomics offers a more efficient alternative for rapid target prediction and screening. Here, we present a computational pipeline combining LC–MS/MS metabolomics, network pharmacology, and molecular docking to identify bioactive scaffolds. We applied this approach to the methanolic extract of the Antarctic moss Chorisodontium aciphyllum as a model matrix. Profiling the bioactive fraction (Fr.3) identified 17 secondary metabolites, primarily featuring fatty acid and steroidal scaffolds. Network pharmacology and functional annotation predicted ERBB2 and AKT1 as key protein targets for anti‐lung cancer activity. Molecular docking supported these predictions, showing that steroidal and secosteroidal compounds such as 5α‐ergosta‐7,22‐diene‐3β,5‐diol and 25‐hydroxyvitamin D2 exhibit high binding affinities to these targets. As a preliminary in vitro validation of the computationally predicted pathways, we found that Fr.3 significantly increased intracellular reactive oxygen species (ROS) levels and induced apoptosis‐mediated cell death in LLC1 murine lung cancer cells (IC 50 ≈ 45.79 µg/mL). Our findings demonstrate that combining untargeted metabolomics with computational analysis can effectively streamline the discovery of therapeutic leads from uncharacterized natural extracts.
- 5 November 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (11)
Open AccessIntegrated Computational Pipeline Combining Metabolomics and Network Pharmacology for Bioactive Scaffold Discovery: Application to Antarctic Moss Chorisodontium aciphyllum
Discovering lead compounds from complex natural matrices traditionally requires resource‐intensive isolation steps. Integrating computational biology with untargeted metabolomics offers a more efficient alternative for rapid target prediction and screening. Here, we present a computational pipeline combining LC–MS/MS metabolomics, network pharmacology, and molecular docking to identify bioactive scaffolds. We applied this approach to the methanolic extract of the Antarctic moss Chorisodontium aciphyllum as a model matrix. Profiling the bioactive fraction (Fr.3) identified 17 secondary metabolites, primarily featuring fatty acid and steroidal scaffolds. Network pharmacology and functional annotation predicted ERBB2 and AKT1 as key protein targets for anti‐lung cancer activity. Molecular docking supported these predictions, showing that steroidal and secosteroidal compounds such as 5α‐ergosta‐7,22‐diene‐3β,5‐diol and 25‐hydroxyvitamin D2 exhibit high binding affinities to these targets. As a preliminary in vitro validation of the computationally predicted pathways, we found that Fr.3 significantly increased intracellular reactive oxygen species (ROS) levels and induced apoptosis‐mediated cell death in LLC1 murine lung cancer cells (IC 50 ≈ 45.79 µg/mL). Our findings demonstrate that combining untargeted metabolomics with computational analysis can effectively streamline the discovery of therapeutic leads from uncharacterized natural extracts.
- 27 April 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 181, 116691
Mycobacterial fusion protein REA eliciting anti-tumor activity through activation of innate immunity
- 27 April 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 181, 116691
Mycobacterial fusion protein REA eliciting anti-tumor activity through activation of innate immunity
- Open Access
- 6 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
IFN-γ and IL-17 elicit synergistic anti-mycobacterial responses by inhibiting coronin-1A retention
CD4+IFN-γ+IL-17+ T cells and their secreted cytokines play a critical role in the anti-mycobacterial response. However, the underlying synergistic mechanism of IFN-γ and IL-17 is little known. This study demonstrates that the downregulation of coronin-1A retention on the phagosome is a synergistic pathway for IFN-γ and IL-17 that kills Mycobacterium tuberculosis (Mtb) in macrophages. IL-17 alone does not play a role in intracellular Mtb killing but potentiates the anti-mycobactericidal pathway of IFN-γ. Co-treatment of IFN-γ/IL-17 inhibited phosphorylation of STAT3, induced LRG47 expression, and reduced retention of coronin-1A on phagosome, thereby eliciting phagolysosomal fusion and bacterial killing, which was proved through response analysis of IFN-γ/IL-17 in Mtb-infected macrophages transfected with small interfering RNA of coro1a, lrg47, or stat1. Determination of adjunctive therapeutic effect of IFN-γ, IL-17, or both with anti-mycobacterial drugs showed that the bacterial load in the tissue of mice co-treated with IFN-γ/IL-17, even at 1 ng/mL concentration each, was more rapidly reduced compared to those of IFN-γ injection or chemotherapy alone. It inhibited the re-growth after treatment termination. Our results shed new light on the synergistic mechanisms of IFN-γ/IL-17 for anti-mycobacterial responses, which might be targeted as an adjunctive chemotherapeutic method against tuberculosis.
- 6 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessIFN-γ and IL-17 elicit synergistic anti-mycobacterial responses by inhibiting coronin-1A retention
CD4+IFN-γ+IL-17+ T cells and their secreted cytokines play a critical role in the anti-mycobacterial response. However, the underlying synergistic mechanism of IFN-γ and IL-17 is little known. This study demonstrates that the downregulation of coronin-1A retention on the phagosome is a synergistic pathway for IFN-γ and IL-17 that kills Mycobacterium tuberculosis (Mtb) in macrophages. IL-17 alone does not play a role in intracellular Mtb killing but potentiates the anti-mycobactericidal pathway of IFN-γ. Co-treatment of IFN-γ/IL-17 inhibited phosphorylation of STAT3, induced LRG47 expression, and reduced retention of coronin-1A on phagosome, thereby eliciting phagolysosomal fusion and bacterial killing, which was proved through response analysis of IFN-γ/IL-17 in Mtb-infected macrophages transfected with small interfering RNA of coro1a, lrg47, or stat1. Determination of adjunctive therapeutic effect of IFN-γ, IL-17, or both with anti-mycobacterial drugs showed that the bacterial load in the tissue of mice co-treated with IFN-γ/IL-17, even at 1 ng/mL concentration each, was more rapidly reduced compared to those of IFN-γ injection or chemotherapy alone. It inhibited the re-growth after treatment termination. Our results shed new light on the synergistic mechanisms of IFN-γ/IL-17 for anti-mycobacterial responses, which might be targeted as an adjunctive chemotherapeutic method against tuberculosis.
- Open Access
- 6 August 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 14 (1) , 2539192
Endogenous hepcidin plays an essential role in Mycobacterium tuberculosis Rv1876 antigen-induced antimicrobial activity in macrophages
Tuberculosis (TB) is one of the most prevalent infectious diseases worldwide. However, few molecules related to bacterial killing within T cell-induced macrophages are known; therefore, elucidating host responses against bacterial components is critical for developing strategies to treat TB. This study investigated the anti-mycobacterial responses induced by Mycobacterium tuberculosis (Mtb) Rv1876 (bacterioferritin A). Rv1876 effectively activated macrophages; however, the protein itself did not elicit bacterial killing. When co-cultured with T cells (Rv1876-T cell), Mtb growth was substantially inhibited in Rv1876-activated macrophages. Rv1876-T cells enhanced endogenous hepcidin expression, an antimicrobial peptide, in Mtb-infected macrophages, which was co-localized adjacent to bacteria-containing phagosomes and directly interacted with them. Other major mycobacterial proteins and bacterioferritin B (Rv3841) did not induce hepcidin in Mtb-infected macrophages, irrespective of T cell involvement. These findings suggest that endogenous hepcidin induced by Rv1876-T cells may be a host bactericidal response and a promising target for host-directed therapies.
- 6 August 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 14 (1) , 2539192
Open AccessEndogenous hepcidin plays an essential role in Mycobacterium tuberculosis Rv1876 antigen-induced antimicrobial activity in macrophages
Tuberculosis (TB) is one of the most prevalent infectious diseases worldwide. However, few molecules related to bacterial killing within T cell-induced macrophages are known; therefore, elucidating host responses against bacterial components is critical for developing strategies to treat TB. This study investigated the anti-mycobacterial responses induced by Mycobacterium tuberculosis (Mtb) Rv1876 (bacterioferritin A). Rv1876 effectively activated macrophages; however, the protein itself did not elicit bacterial killing. When co-cultured with T cells (Rv1876-T cell), Mtb growth was substantially inhibited in Rv1876-activated macrophages. Rv1876-T cells enhanced endogenous hepcidin expression, an antimicrobial peptide, in Mtb-infected macrophages, which was co-localized adjacent to bacteria-containing phagosomes and directly interacted with them. Other major mycobacterial proteins and bacterioferritin B (Rv3841) did not induce hepcidin in Mtb-infected macrophages, irrespective of T cell involvement. These findings suggest that endogenous hepcidin induced by Rv1876-T cells may be a host bactericidal response and a promising target for host-directed therapies.
- Open Access
- 31 March 2025
- Published by The Korean Society for Microbiology and The Korean Society of Virology in Journal of Bacteriology and Virology
- Vol. 55 (1) , 69-78
A Novel Inhibitor of Acetohydroxyacid Synthase with Pan-antimycobacterial Activity
- 31 March 2025
- Published by The Korean Society for Microbiology and The Korean Society of Virology in Journal of Bacteriology and Virology
- Vol. 55 (1) , 69-78
Open AccessA Novel Inhibitor of Acetohydroxyacid Synthase with Pan-antimycobacterial Activity
- Open Access
- 31 January 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-15
Novel fusion protein REA induces robust prime protection against tuberculosis in mice
While many novel candidates for tuberculosis vaccines are presently undergoing pre-clinical or clinical trials, none of them have been able to eliminate infection entirely. In this study, we engineered a potent chimeric protein vaccine candidate, Rv2299cD2D3-ESAT-6-Ag85B (REA), which induced Th1 and Th17 responses via dendritic cell maturation. REA-activated macrophages operated the killing mechanisms of Mycobacterium tuberculosis (MTB), such as phagosomal maturation and phagolysosome fusion, through the (PI3K)–p38 MAPK-Ca2+-NADPH oxidase pathway. Dendritic cells and macrophages activated by REA elicited synergistic anti-mycobacterial responses. Notably, REA-immunized mice suppressed MTB growth to undetectable levels at 16 weeks post-infection, which was supported by gross and pathologic findings and acid-fast staining of the lung tissues, and maintained antigen-specific multifunctional IFN-γ+IL-2+TNF-α CD4+ T and long-lasting T cells producing cytokines in the tissues. Our findings suggest that REA is an outstanding prime prophylactic vaccine candidate against tuberculosis.
- 31 January 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-15
Open AccessNovel fusion protein REA induces robust prime protection against tuberculosis in mice
While many novel candidates for tuberculosis vaccines are presently undergoing pre-clinical or clinical trials, none of them have been able to eliminate infection entirely. In this study, we engineered a potent chimeric protein vaccine candidate, Rv2299cD2D3-ESAT-6-Ag85B (REA), which induced Th1 and Th17 responses via dendritic cell maturation. REA-activated macrophages operated the killing mechanisms of Mycobacterium tuberculosis (MTB), such as phagosomal maturation and phagolysosome fusion, through the (PI3K)–p38 MAPK-Ca2+-NADPH oxidase pathway. Dendritic cells and macrophages activated by REA elicited synergistic anti-mycobacterial responses. Notably, REA-immunized mice suppressed MTB growth to undetectable levels at 16 weeks post-infection, which was supported by gross and pathologic findings and acid-fast staining of the lung tissues, and maintained antigen-specific multifunctional IFN-γ+IL-2+TNF-α CD4+ T and long-lasting T cells producing cytokines in the tissues. Our findings suggest that REA is an outstanding prime prophylactic vaccine candidate against tuberculosis.
- 13 December 2024
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 78 (3) , 181-189
Inhibitors of acetohydroxyacid synthase as promising agents against non-tuberculous mycobacterial diseases
Acetohydroxyacid synthase (AHAS), exclusively present in microorganisms and plants, is a promising target for several herbicides due to its catalytic role in the branched-chain amino acid biosynthetic pathway. Previous studies have shown that K13787, a pyrazolopyrimidine sulfonamide AHAS inhibitor, was moderately effective against pulmonary infection caused by M. tuberculosis and nontuberculous mycobacteria (NTM). In this study, we synthesized various structural derivatives of K13787 based on the molecular docking studies and assessed their MICs against mycobacteria species. Among the synthetic compounds screened, K13787, along with KNT2077 and KNT2099, exhibited inhibitory efficacy against M. avium and M. abscessus, including CLR-resistant NTM species. Notably, these compounds displayed a synergistic effect (FIC ≤ 0.5) when combined with CLR against M. avium and M. abscessus. Our findings suggest that these newly identified AHAS-targeted compounds hold promise as lead candidates for novel antimycobacterial agents against NTM infections. Considering the structure-activity relationship, K13787, KNT2077, and KTN2099 emerge as potential treatments for NTM species.
- 13 December 2024
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 78 (3) , 181-189
Inhibitors of acetohydroxyacid synthase as promising agents against non-tuberculous mycobacterial diseases
Acetohydroxyacid synthase (AHAS), exclusively present in microorganisms and plants, is a promising target for several herbicides due to its catalytic role in the branched-chain amino acid biosynthetic pathway. Previous studies have shown that K13787, a pyrazolopyrimidine sulfonamide AHAS inhibitor, was moderately effective against pulmonary infection caused by M. tuberculosis and nontuberculous mycobacteria (NTM). In this study, we synthesized various structural derivatives of K13787 based on the molecular docking studies and assessed their MICs against mycobacteria species. Among the synthetic compounds screened, K13787, along with KNT2077 and KNT2099, exhibited inhibitory efficacy against M. avium and M. abscessus, including CLR-resistant NTM species. Notably, these compounds displayed a synergistic effect (FIC ≤ 0.5) when combined with CLR against M. avium and M. abscessus. Our findings suggest that these newly identified AHAS-targeted compounds hold promise as lead candidates for novel antimycobacterial agents against NTM infections. Considering the structure-activity relationship, K13787, KNT2077, and KTN2099 emerge as potential treatments for NTM species.
- Open Access
- 23 November 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-16
Enhancing antitumor immunity in Lewis lung cancer through plasma-treated medium-induced activation of dendritic cells
Recently, atmospheric non-thermal plasma jet-treated medium (PTM) has been recognized as a novel strategy in cancer therapy and lymphocyte activation. However, PTM has limitations in inducing a robust antitumor-immune response. This study demonstrated that PTM treatment inhibited tumor progression by activating dendritic cells (DCs). In this study, we investigated the effects of PTM on selective cytotoxicity and intracellular reactive oxygen species (ROS) generation and oxidative stress-mediated signaling (e.g., glutathione peroxidase, catalase) using respective fluorescence probes in Lewis lung cancer (LLC) cells. Then, the PTM affects the expression of interferon-gamma (IFN)-γ-induced programmed death-ligand 1 (PD-L1) and inhibition of signal transducer and activator of transcription 1 (STAT1) in LLC cells using immunoblotting. Additionally, PTM effects on the tumor cell’s death and activation of DCs were done by co-culturing DCs with or without tumor cells. Further, a mouse model was used to evaluate the synergistic antitumor effects of PTM and DCs where tumors are grown under the skin. PTM-exposed tumor cells increase intracellular superoxide production, enhancing ROS generation and leading to cancer immunogenic cell death. In addition, PTM suppresses IFN-γ-induced PD-L1 expression and STAT1 activation in tumor cells. The activation of DCs induced by PTM is downregulated when these cells are co-cultured with tumor cells. In vivo, intraperitoneal injection of PTM-activated DCs, as a synergistic agent to intertumoral PTM treatment, led to increased CD4+ and CD8+ T cell infiltration into the tumor and spleen and eventually decreased tumor growth. Overall, this research introduces a promising avenue for improving lung cancer treatment using PTM to stimulate an immune response and induce cell death in tumor cells. Further studies will be essential to validate these findings and explore clinical applications.
- 23 November 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-16
Open AccessEnhancing antitumor immunity in Lewis lung cancer through plasma-treated medium-induced activation of dendritic cells
Recently, atmospheric non-thermal plasma jet-treated medium (PTM) has been recognized as a novel strategy in cancer therapy and lymphocyte activation. However, PTM has limitations in inducing a robust antitumor-immune response. This study demonstrated that PTM treatment inhibited tumor progression by activating dendritic cells (DCs). In this study, we investigated the effects of PTM on selective cytotoxicity and intracellular reactive oxygen species (ROS) generation and oxidative stress-mediated signaling (e.g., glutathione peroxidase, catalase) using respective fluorescence probes in Lewis lung cancer (LLC) cells. Then, the PTM affects the expression of interferon-gamma (IFN)-γ-induced programmed death-ligand 1 (PD-L1) and inhibition of signal transducer and activator of transcription 1 (STAT1) in LLC cells using immunoblotting. Additionally, PTM effects on the tumor cell’s death and activation of DCs were done by co-culturing DCs with or without tumor cells. Further, a mouse model was used to evaluate the synergistic antitumor effects of PTM and DCs where tumors are grown under the skin. PTM-exposed tumor cells increase intracellular superoxide production, enhancing ROS generation and leading to cancer immunogenic cell death. In addition, PTM suppresses IFN-γ-induced PD-L1 expression and STAT1 activation in tumor cells. The activation of DCs induced by PTM is downregulated when these cells are co-cultured with tumor cells. In vivo, intraperitoneal injection of PTM-activated DCs, as a synergistic agent to intertumoral PTM treatment, led to increased CD4+ and CD8+ T cell infiltration into the tumor and spleen and eventually decreased tumor growth. Overall, this research introduces a promising avenue for improving lung cancer treatment using PTM to stimulate an immune response and induce cell death in tumor cells. Further studies will be essential to validate these findings and explore clinical applications.
- Open Access
- 8 March 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-12
BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice
The quest for effective and enhanced multiantigenic tuberculosis (TB) subunit vaccine necessitates the induction of a protective pathogen-specific immune response while circumventing detrimental inflammation within the lung milieu. In line with this goal, we engineered a modified iteration of the quadrivalent vaccine, namely HSP90-ESAT-6-HspX-RipA (HEHR), which was coupled with the TLR4 adjuvant, CIA09A. The ensuing formulation was subjected to comprehensive assessment to gauge its protective efficacy against the hypervirulent Mycobacterium tuberculosis (Mtb) Haarlem clinical strain M2, following a BCG-prime boost regimen. Regardless of vaccination route, both intramuscular and subcutaneous administration with the HEHR vaccine exhibited remarkable protective efficacy in significantly reducing the Mtb bacterial burden and pulmonary inflammation. This underscores its notably superior protective potential compared to the BCG vaccine alone or a former prototype, the HSP90-E6 subunit vaccine. In addition, this superior protective efficacy was confirmed when testing a tag-free version of the HEHR vaccine. Furthermore, the protective immune determinant, represented by durable antigen-specific CD4+IFN-γ+IL-17A+ T-cells expressing a CXCR3+KLRG1- cell surface phenotype in the lung, was robustly induced in HEHR-boosted mice at 12 weeks post-challenge. Collectively, our data suggest that the BCG-prime HEHR boost vaccine regimen conferred improved and long-term protection against hypervirulent Mtb strain with robust antigen-specific Th1/Th17 responses.
- 8 March 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-12
Open AccessBCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice
The quest for effective and enhanced multiantigenic tuberculosis (TB) subunit vaccine necessitates the induction of a protective pathogen-specific immune response while circumventing detrimental inflammation within the lung milieu. In line with this goal, we engineered a modified iteration of the quadrivalent vaccine, namely HSP90-ESAT-6-HspX-RipA (HEHR), which was coupled with the TLR4 adjuvant, CIA09A. The ensuing formulation was subjected to comprehensive assessment to gauge its protective efficacy against the hypervirulent Mycobacterium tuberculosis (Mtb) Haarlem clinical strain M2, following a BCG-prime boost regimen. Regardless of vaccination route, both intramuscular and subcutaneous administration with the HEHR vaccine exhibited remarkable protective efficacy in significantly reducing the Mtb bacterial burden and pulmonary inflammation. This underscores its notably superior protective potential compared to the BCG vaccine alone or a former prototype, the HSP90-E6 subunit vaccine. In addition, this superior protective efficacy was confirmed when testing a tag-free version of the HEHR vaccine. Furthermore, the protective immune determinant, represented by durable antigen-specific CD4+IFN-γ+IL-17A+ T-cells expressing a CXCR3+KLRG1- cell surface phenotype in the lung, was robustly induced in HEHR-boosted mice at 12 weeks post-challenge. Collectively, our data suggest that the BCG-prime HEHR boost vaccine regimen conferred improved and long-term protection against hypervirulent Mtb strain with robust antigen-specific Th1/Th17 responses.
- Open Access
A Structural View at Vaccine Development against M. tuberculosis
Tuberculosis (TB) is still the leading global cause of death from an infectious bacterial agent. Limiting tuberculosis epidemic spread is therefore an urgent global public health priority. As stated by the WHO, to stop the spread of the disease we need a new vaccine, with better coverage than the current Mycobacterium bovis BCG vaccine. This vaccine was first used in 1921 and, since then, there are still no new licensed tuberculosis vaccines. However, there is extremely active research in the field, with a steep acceleration in the past decades, due to the advance of technologies and more rational vaccine design strategies. This review aims to gather latest updates in vaccine development in the various clinical phases and to underline the contribution of Structural Vaccinology (SV) to the development of safer and effective antigens. In particular, SV and the development of vaccine adjuvants is making the use of subunit vaccines, which are the safest albeit the less antigenic ones, an achievable goal. Indeed, subunit vaccines overcome safety concerns but need to be rationally re-engineered to enhance their immunostimulating effects. The larger availability of antigen structural information as well as a better understanding of the complex host immune response to TB infection is a strong premise for a further acceleration of TB vaccine development.
Open AccessA Structural View at Vaccine Development against M. tuberculosis
Tuberculosis (TB) is still the leading global cause of death from an infectious bacterial agent. Limiting tuberculosis epidemic spread is therefore an urgent global public health priority. As stated by the WHO, to stop the spread of the disease we need a new vaccine, with better coverage than the current Mycobacterium bovis BCG vaccine. This vaccine was first used in 1921 and, since then, there are still no new licensed tuberculosis vaccines. However, there is extremely active research in the field, with a steep acceleration in the past decades, due to the advance of technologies and more rational vaccine design strategies. This review aims to gather latest updates in vaccine development in the various clinical phases and to underline the contribution of Structural Vaccinology (SV) to the development of safer and effective antigens. In particular, SV and the development of vaccine adjuvants is making the use of subunit vaccines, which are the safest albeit the less antigenic ones, an achievable goal. Indeed, subunit vaccines overcome safety concerns but need to be rationally re-engineered to enhance their immunostimulating effects. The larger availability of antigen structural information as well as a better understanding of the complex host immune response to TB infection is a strong premise for a further acceleration of TB vaccine development.